Big Dreams, Bold Progress
You may say that we are dreamers...

In 1949, The Leukemia & Lymphoma Society (LLS) was founded on a dream, by parents who’d lost a son to acute lymphoblastic leukemia and sought to spare others their pain.

Since then, LLS has never stopped dreaming. Our bold achievements continue to push boundaries as we seek cutting edge treatments and cures and work to improve quality of life for patients and their families.

Our progress has been nothing short of astonishing.

2022 was no exception. Take a look...
With your help, we are creating a world where cancer patients not only survive their blood cancer but thrive in their lives after treatment.

The evolution of new blood cancer therapies has been breathtaking—spanning the gamut from gene-targeted therapies to cell-based immunotherapies—and providing remarkable benefit to patients.

The Leukemia & Lymphoma Society (LLS) is the largest nonprofit funder of blood cancer research, having invested more than $1.6 billion since our founding. In the last six years alone, we have helped advance more than 70% of the 110 (!) blood cancer treatment options approved by the U.S. Food and Drug Administration.

But LLS does more than fund pioneering research. We’re here to support patients and families through every part of their blood cancer experience—from diagnosis through treatment and beyond. We provide the reassurance, free personalized information and financial assistance they need. And we advocate for policies that break down barriers to care, so it’s more accessible and affordable for those in underserved communities.

At LLS, we envision a world without blood cancer. We work toward that dream every day and have made bold progress in our mission to cure blood cancers and improve the quality of life for patients and their families.

I am exceptionally proud of what we’ve accomplished together and excited about all that’s on the horizon.

Louis J. DeGennaro, PhD | President and Chief Executive Officer

In 2004, I was diagnosed with acute myeloid leukemia (AML) and given a 40% chance to live. I was one of the lucky survivors—thanks to pioneering scientists who created medicine that cured me. Once in remission, I resolved to do whatever I could to help blood cancer patients and to accelerate the development of new treatments so that more patients could survive these terrible blood cancers.

I searched for a nonprofit to support and found in LLS an organization that not only deploys its donations responsibly and effectively in service of patients but is transforming blood cancer treatment and care.

I’ve been fundraising and volunteering for LLS ever since—first as a member of the Georgia board, then as part of LLS’s national board, and now proudly as National Board Chair. I believe there’s no better use of our time and talents than helping others.

Your support has lifesaving and life-changing power. Through your generosity of heart and spirit, you are helping LLS ensure a future of expanded hope for all blood cancer patients and those who love and care for them.

I am grateful for you and the sacrifices you make to help others. Thank you.

Jeff Sachs | Chair of the Board
Transforming Treatment and Care for Kids with Blood Cancer

Our Bold Progress
At LLS, our pediatric triumphs help make the case that dreams can come true. Cancers previously associated with nearly certain death are now highly survivable. Through our Children's Initiative, we have supported breakthrough research, developed programs to support pediatric patients and families, and sparked interest among leading experts in pediatric oncology. But LLS knows there is more to accomplish, and in 2022, we deepened our commitment to further galvanize progress with the next phase of our Children's Initiative: The Dare to Dream Project. With an expanded vision, and a name that reflects our belief that this big, bold project is achievable, we are aiming higher than ever before: a total transformation of treatment for children with blood cancer through a 360-degree, holistic approach. With a five-year fundraising goal of $175M, our efforts are in full swing to...

...Bring Safer Treatments to Children Through Our PedAL Master Clinical Trial
LLS is committed to ensuring long-term quality-of-life for the youngest blood cancer patients. Our goal is to uncover less toxic individualized therapies that target cancer cells, spare healthy cells, and avoid adverse long-term health consequences. The 2022 launch of LLS' Pediatric Acute Leukemia (PedAL) Master Clinical Trial marked a critical milestone in this quest. This unprecedented international collaborative effort between LLS, the National Cancer Institute (NCI), the Children's Oncology Group (COG), and other partners and sponsors breaks new ground, bringing precision medicine to the treatment of pediatric relapsed acute leukemia.

Rather than a “one size fits all” approach, PedAL uses genomics and other biomarkers to customize treatment, allowing innovative therapies to be matched to patients based on their unique tumor biology. A wide range of trial screening locations—spanning Europe, Australia, New Zealand, Canada, and over 200 U.S. sites—ensures widespread participation. Arkansas Children’s Hospital became the first U.S. therapeutic trial site in 2022, with more to come.

Two LLS-supported digital breakthroughs led by the University of Chicago are contributing to PedAL’s robust data infrastructure, allowing for standardized assessment of tumor biology and global data sharing:

- GEARBOx (Genomic Eligibility Algorithm at Relapse for Better Outcomes): a search tool that helps physicians match relapsed leukemia patients to available clinical trials
- Data Commons: a platform that ensures consistency in global data reporting, analysis, and access

"Children have a unique disease with unique targets. Efforts like PedAL are critical to address the specific needs of our youngest, most vulnerable patients by using new, safer therapies."

— Dr. Todd Cooper, section chief of Pediatric Oncology; director of the Pediatric Leukemia/Lymphoma Program; co-director of the High-Risk Leukemia Program at Seattle Children's; PedAL screening trial lead
MEET Cayden & Courtney Addison

One Family’s Journey Toward Hope

When three-year-old Cayden Addison of Chesapeake, VA, was diagnosed with high-risk Philadelphia Chromosome-positive acute lymphoblastic leukemia (ALL), his mom Courtney “sobbed like never before.” From that point forward, Courtney knew she’d embrace a dual mission: to learn all she could about blood cancer, while getting Cayden through the surgeries, chemotherapy, and countless overnight hospital stays he would need to endure.

A recommendation from a friend connected the Addisons to LLS’ flagship Light The Night fundraising campaign and before long, Cayden was named the campaign’s 2021 National Honored Hero, serving as an LLS Ambassador of Hope. Involvement with LLS has provided needed support for Courtney during Cayden’s cancer journey. “Through LLS, I’ve learned there is a whole community of people out there who were just as passionate and dedicated to fighting this disease as I am.” Cayden finished treatment in April 2022, and Courtney has drawn hope and strength from a “brave, strong, resilient, and grateful” Cayden... and from LLS. Courtney now serves as a Dare to Dream Ambassador, sharing her family’s story to raise awareness about LLS and the need for better treatments. “I know LLS’ great work is helping bring us closer to a world where no parent has to hear, ‘your child has cancer.’”

...Expedite Groundbreaking Pediatric Blood Cancer Research Through Increased Investment

LLS seeks to improve our understanding of all pediatric blood cancers and develop better, safer treatments so as many patients as possible survive without lifelong health challenges. We have increased our pediatric research investment significantly, with a commitment to invest more than $52M in pediatric grants by 2027. In FY22 alone, our $8.4M commitment to pediatric blood cancer projects represented a four-fold increase compared to FY21. Like PedAL, all our laboratory research efforts explore therapeutics that consider the unique genetics of pediatric blood cancers and replace “one size fits all” chemotherapy with targeted treatments. We are funding over 30 pediatric-specific grants, including work focused on long-term side effects of treatment and improved relapse detection.

...Grow Our Education & Support Services

To provide 360-degree support for pediatric patients and families, we are expanding our educational resources and support services, with the emphasis on providing guidance, information, and comfort during treatments...and beyond. In 2022, we introduced our hardcover book trilogy, Stars Will Twinkle, The Sun Will Shine, available in English and Spanish, to educate pre-kindergarten children about a leukemia diagnosis—the first book in the U.S. to do so. Further, our Caregivers’ Guide to Navigating Childhood and Adolescent Blood Cancers, a digital “flip book” embedded with videos, was selected as a Gold Award Winner in the Spring 2022 Digital Health Awards. Additionally, we added specially trained pediatric nurse navigators to help families navigate the clinical trial process within our LLS Clinical Trial Support Center (CTSC).

...Drive Advocacy for Young Patients and Families

For decades, LLS has fought to ensure access to affordable, quality healthcare for kids and young adults with blood cancer. Moreover, we’ve pushed to change outdated policies that stall pediatric drug development. In 2022, volunteer advocates and staff working closely with allies helped secure $160M in federal funds for pediatric cancer research nationwide. That funding was the result of hundreds of constituent meetings with lawmakers emphasizing the importance of those dollars for patients. LLS advocates also sent thousands of letters to lawmakers and held hundreds of meetings, resulting in Congress extending the Childhood Cancer STAR Act—the most comprehensive childhood cancer bill ever—for another five years.
**Breakthrough Research: Improving Treatments and Enhancing Quality of Life**

<table>
<thead>
<tr>
<th>RESEARCH INVESTMENT: $233.8 MILLION</th>
<th>$62M AML</th>
<th>$44M AGGRESSIVE NHL</th>
<th>$32M MYELOMA</th>
<th>$26M MDS/MPNS</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL MULTI-YEAR FUNDING IN RESEARCH</td>
<td>26.5%</td>
<td>18.6%</td>
<td>13.5%</td>
<td>11.2%</td>
</tr>
<tr>
<td>$19M GENERAL LYMPHOMA</td>
<td>$16M INDOLENT NHL</td>
<td>$14M ALL</td>
<td>$10M GENERAL LEUKEMIA</td>
<td>$5M CLL/SLL</td>
</tr>
<tr>
<td>7.9%</td>
<td>6.9%</td>
<td>6.1%</td>
<td>4.4%</td>
<td>2.2%</td>
</tr>
<tr>
<td>$5M HODGKIN LYMPHOMA</td>
<td>$5M CML</td>
<td>$2M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1%</td>
<td>0.7%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Any discrepancies are due to rounding; total investment=$233.8M.

**Advancing Science**

**Big Dreams**

To discover breakthrough treatments and cures for all blood cancers and improve quality of life during and after treatment...bringing new hope to even more patients.

**Our Bold Progress**

LLS is the largest nonprofit funder of blood cancer research and has been instrumental in the development of nearly every breakthrough in its treatment. Because of LLS, blood cancers that were once fatal are now treatable and even curable.

LLS is proud of our role in advancing treatments that have exponentially improved survival rates and quality of life for patients with many types of blood cancer, but there is much more for us to accomplish.

**Our Strategic Approach**

LLS has a history of strategic investment in the most innovative and promising blood cancer research, leading to an unparalleled record of success. Today, blood cancer patients are living longer, better lives because LLS has supported generations of remarkable scientists leading to extraordinary advances. We put our support where it will make a real difference:

- Last year alone, **LLS Research Grants supported 117 scientists** at the world’s most prestigious institutions to advance next-generation approaches including immunotherapy, gene editing and precision medicine.
• Therapy Acceleration Program® (TAP) is a unique venture philanthropy initiative partnering directly with biotechnology companies to invest in innovative therapies to change the standard of blood cancer care.

Since 2017, four TAP-supported therapies have been approved by the FDA or added to guidelines that drive treatment and insurance coverage decisions. Currently, there are more than 20 active clinical studies of TAP-supported therapies, including four that, if successful, will lead to additional new FDA approvals.

• The first of their kind LLS-Led Master Clinical Trials, Beat AML® and PedAL (Pediatric Acute Leukemia), have brought together a broad, global collaboration with some of the best and brightest industry leaders and academic institutions to fundamentally change treatment for adults and children.

Here are some highlights of how LLS is shaping the research landscape and the exciting work ongoing:

Immunotherapy

Immunotherapy harnesses the power of the immune system to attack cancer. LLS has invested more than $100 million in immunotherapy and our commitment is stronger than ever. Our early and sustained investment was vital to the development of CAR T-immunotherapy, which re-engineers a patient’s own immune T cells to fight their cancer.

With 12 approvals since 2017, and 4 in 2022 alone, CAR T is providing a lifeline for patients with acute lymphocytic leukemia, multiple myeloma and non-Hodgkin lymphomas. This year also saw approval of a first-in-class bispecific antibody to treat multiple myeloma. Bispecific antibodies attach to both tumor cells and immune T cells to activate them to attack the cancer.

Our ongoing investments are aimed at making immunotherapy available earlier in treatment and to patients with more types of blood cancer, shortening the time it takes to deliver CAR-T, and harnessing parts of the immune system beyond T cells to make treatments even better and longer lasting.

Precision Medicine

Blood cancer treatment has been revolutionized, thanks to precision medicine. By attacking cancer cells based on their unique genetic characteristics while leaving healthy cells alone, precision medicine helps to avoid short- and long-term side effects of conventional “one-size-fits-all” chemotherapies.

The FDA approved 13 new precision medicine treatments for blood cancers this year. We helped advance many of these new drugs and continue to invest in research to better understand the genetic underpinnings of blood cancer, discover new targets, and uncover new combination therapies. Through LLS’s Beat AML® and PedAL master clinical trials, LLS is unlocking the power of
Dr. Noha Sharafeldin

**LLS Propels Young Scientist's Bold Progress**

While studying medicine in her native Egypt, and later for her PhD in Canada, Dr. Noha Sharafeldin sought to understand how certain factors—including genetics—make some people more susceptible to cancer. During her postdoctoral studies at the University of Alabama at Birmingham (UAB), her blood cancer outcomes and survivorship research caught the attention of LLS, earning her a Career Development Program (CDP) Special Fellow Award in 2018.

Dr. Sharafeldin credits LLS with “providing financial support and stability” that kept her “on track and focused” as she researched how to reduce long-term cognitive effects of bone marrow transplants on blood cancer survivors. “The CDP Fellow award was absolutely instrumental to my career,” she said, explaining that, besides funding, the recognition gave her “confidence…and the will to overcome challenges as an international scholar.”

Dr. Sharafeldin gives back to LLS as a member of her local LLS Students of the Year leadership team. Now an assistant professor of medicine at UAB and member of its Institute for Cancer Outcomes and Survivorship, she was recognized again in 2022, receiving the LLS-CDP Special Fellow Achievement Award. As one of four grantees honored as most impressive in the final year of their funding, Dr. Sharafeldin is hopeful that, as the survivor population grows, “efforts to reduce the negative impact on quality-of-life after cancer will be at the forefront,” adding that she will be “eternally grateful watching LLS move our field forward.”

**Impact of Covid**

Throughout the pandemic, the LLS National Patient Registry, a project of the Michael J. Garil Patient Data Collective, has generated essential information about the impact of COVID-19 and COVID-19 vaccines on the blood cancer community. Our findings have helped patients and their families make informed vaccine and prevention choices and have shaped public policies designed to help them stay safer during this uniquely challenging time. Our current focus is on reporting critical data on breakthrough infections in blood cancer patients, including those who have received monoclonal antibodies to reduce the chances of COVID-19 infections.

**Prevention**

The ability to intercept blood cancer at its earliest, most treatable stages, or even before it occurs, is becoming increasingly possible, thanks to high-powered genetic analysis that can identify patients with cancer-causing blood gene mutations.

Earlier this year, LLS-supported research reported that first responders to the World Trade Center attack on 9-11 have significantly higher rates of mutations in their blood associated with certain blood cancers, providing rationale for enhanced screening and prevention efforts for these heroes. With our support, an LLS advocate led an effort to secure an additional $1 million grant from New York State to help fund this project.

LLS is also funding a clinical study in Iceland to identify patients with an early precursor of multiple myeloma, known as MGUS (monoclonal gammopathy of undetermined significance), and follow their progression to myeloma. Iceland’s unique nationalized health system allows for tracking MGUS progression in a large population.

**Gene Editing**

The ability to edit or replace defective genes is a promising new area for blood cancer discoveries and therapies. LLS is once again at the forefront by funding research using gene editing approaches to find new treatments and improve existing treatments. LLS TAP partner Caribou Biosciences, for example, is exploring using next-generation CRISPR genome-editing to eliminate a gene that shuts down T-cells, to hopefully sustain or even boost activity of CAR T cell treatment.
Funding The Next Generation Of Breakthroughs

LLS funds innovative research and researchers across the U.S. and the world who are working on better treatments for all types of blood cancer, including...

Omar Abdel-Wahab, MD
Memorial Sloan Kettering Cancer Center
Developing new targeted therapies for every stage and subtype of hairy cell leukemia

Matteo Bellone, MD
Fondazione Centro San Raffaele, Italy
Investigating whether a vaccine to modulate bacteria in the gut can block the progression of multiple myeloma to full-blown disease

Timothy Graubert, MD
Massachusetts General Hospital
Building the foundational science needed to launch multiple clinical trials to test therapies for patients with mutations that make treatment more challenging

Richard Lock, PhD
The University of New South Wales, Australia
Testing a potential treatment for ALL, the most common pediatric blood cancer and one of the most common causes of death from disease in children

Julia Maxson, PhD
Knight Cancer Institute, Oregon Health & Science University
Identifying multipronged strategies to improve outcomes for patients with myeloid cancers, such as AML and chronic neutrophilic leukemia

Catherine Smith, MD
University of California, San Francisco
Working to identify the genetic mutations that can make acute myeloid leukemia resistant to conventional therapy, and developing novel treatment strategies

Srividya Swaminathan, PhD
Beckman Research Institute of the City of Hope
Studying how cancer cells avoid immune system detection in children and adults with lymphoid malignancies including acute lymphoblastic leukemia and lymphomas

Ryan Wilcox, MD, PhD
University of Michigan
Investigating a novel therapeutic target to treat an aggressive group of non-Hodgkin lymphomas called T-cell lymphomas
2022 New FDA Approvals

<table>
<thead>
<tr>
<th>Leukemia</th>
<th>Lymphoma</th>
<th>Other Blood Cancers and Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute Myeloid Leukemia with IDH1 mutation</strong>&lt;br&gt;Olutasidenib (Rezlidhia™)&lt;br&gt;Ivosidenib (Tibsovo®) in combination with azacitidine</td>
<td><strong>Follicular Lymphoma</strong>&lt;br&gt;Tisagenlecleucel (Kymriah®)&lt;br&gt;Mosunetuzumab (Lunsumio®)&lt;br&gt;<strong>Pediatric Classical Hodgkin Lymphoma</strong>&lt;br&gt;Brentuximab vedotin (Adcetris®) in combination with chemotherapy</td>
<td><strong>Pediatric Graft Vs Host Disease</strong>&lt;br&gt;Ibrutinib (Imbruvica®)&lt;br&gt;<strong>Histiocytic Neoplasms</strong>&lt;br&gt;Cobimetinib (Cotellic®)&lt;br&gt;<strong>Myelofibrosis (high-risk primary or secondary)</strong>&lt;br&gt;Pacritinib (Vonjo®)&lt;br&gt;<strong>Myeloid/Lymphoid Neoplasms with FGFR1 mutation</strong>&lt;br&gt;Pemigatinib (Pemazyre®)</td>
</tr>
<tr>
<td><strong>Juvenile (Pediatric) Myelomonocytic Leukemia</strong>&lt;br&gt;Azacitidine (Vidaza®)</td>
<td><strong>Large B-cell Lymphoma</strong>&lt;br&gt;(second line treatment)&lt;br&gt;Lisocabtagene maraleucel (Breyanzi®)&lt;br&gt;Axicabtagene ciloleucel (Yescarta®)</td>
<td><strong>Relapsed/Refractory (advanced) disease</strong>&lt;br&gt;Teclistamab-cqyy (Tecvayli™)&lt;br&gt;Ciltacabtagene autoleucel (Carvykti™)</td>
</tr>
</tbody>
</table>
Progress Across All Blood Cancers

Multiple Myeloma

In 2022, two new treatments were approved to treat multiple myeloma—a CAR T-cell treatment in March and the first bispecific antibody in October. These approvals, both immunotherapy drugs, reinforce the long-term LLS strategy of investing in ways to activate the immune system to cure cancer. The new drugs take us one step closer to long-term control of multiple myeloma, but there is much more to do as we work towards a cure.

LLS has more than $31 million committed to more than 30 active laboratory and clinical research projects to improve the health and quality of life of patients with multiple myeloma. We search worldwide for the most innovative ideas, leading us to support a key clinical trial in Iceland that will lead to blocking the progression from pre-myeloma to myeloma. Additional work is focused on identifying mutations that cause the disease, and understanding why patients become resistant to certain treatments, and supporting clinical trials that will overcome resistance to currently approved immunotherapies.

Leukemia

With more than $93 million committed to leukemia research, LLS continues to lead the way toward cures, including with targeted therapies that zero in on specific genetic traits of cancer. We are working toward new standards of care, especially for children, that move away from toxic chemotherapies and toward precision approaches that target cancer cells without harming the rest of their bodies. Newly approved drugs this year for leukemia include a new treatment for a difficult and rare form of childhood leukemia that most often occurs in children before age 4, and a new targeted combination therapy for patients 75 and older with newly diagnosed AML with an IDH1 gene mutation.

Lymphoma

CAR T-cell therapies continue to redefine our approach to many types of lymphoma. As one of the earliest supporters of this groundbreaking immune-based approach, we were excited to see CAR T-therapies approved this year for use earlier in the treatment of large B-cell lymphoma and follicular lymphoma, offering patients a superior long-term remission rate compared to other therapies and the hope of a potential cure. Our work does not stop there. With $83 million dedicated to lymphoma research, we continue to push boundaries to find better and safer treatments for Hodgkin lymphoma and all forms of non-Hodgkin lymphoma. LLS has placed special emphasis on developing new therapies for mantle cell lymphoma, which includes the use of new precision medicines and therapies.

Other Blood Cancers and Conditions

LLS proudly dedicates resources and expertise to research to improve the outlook for people with every type of blood cancer. Our efforts to identify and understand genetic mutations at work in blood cancer laid the foundation for 2022 drug approvals for patients with myeloproliferative neoplasms (MPNs) driven by mutations in genes called JAK2, IRAK1, CSFR1 and FGFR1. These gene names may sound like “alphabet soup,” but identifying these genes and developing drugs that target them is vital to affected patients. LLS has more than $30 million committed to research into MPNs and $26 million committed to improving our ability to diagnose, treat and stop myelodysplastic syndromes from progressing to acute leukemia. Our funding also played a key role in approval of a new precision medicine treatment to control histiocytic neoplasms. LLS funded key laboratory and clinical research leading to approvals for children and adults with this rare cancer.

THE Dream Continues...

Our growing knowledge is paving the way for newer, even more precise immunotherapy and precision medicine approaches, including an increasing number of CAR-T therapies, bispecific antibodies, and other immune-based therapies that can treat even more types of blood cancer and earlier in the course of the disease.
360 Degree Support for the Blood Cancer Community

The Big Dream
That all blood cancer patients—no matter who they are or where they live—receive the best care and support they need from diagnosis to treatment to survivorship.

Our Bold Progress
At LLS, we recognize the financial and emotional impact a blood cancer diagnosis can have on patients and families. We also realize how difficult it is to navigate a complex healthcare system after diagnosis—especially given that there are many barriers to health equity. Our goal is to help ease these burdens by providing all-around support and advocacy for patients, survivors, caregivers, and families. In 2022, we made impressive headway.

Advancing Health Equity

LLS has a long-standing commitment to equity in blood cancer care. Guided by our fundamental belief that everyone deserves the best possible treatment, we have instituted multiple efforts to break down barriers and address the needs of underserved populations.

In 2022, we made meaningful progress as we...

...Increased Funding for Our Equity in Access Research Program
To overcome disparities in health care, we must understand the obstacles. In 2022, we launched this signature program as part of our longstanding effort to understand barriers in blood cancer treatment and identify solutions to improve access to care. We granted over $1.3 million in combined funding for three teams of preeminent researchers, charged with uncovering the root causes of health disparities—information we can use to urge lawmakers and healthcare practitioners to affect positive change.

“Blood cancer is hard enough for patients and their families, and obstacles make it even harder. We want to put an end to these disparities. That’s why LLS created the Equity in Access Research Program.”

— Gwen Nichols, MD, LLS Chief Medical Officer
Charlie’s Law: How one LLS advocate’s work is helping improve diversity of the National Bone Marrow Registry.

After receiving a leukemia diagnosis, Santa Clara County Deputy District Attorney Charles Huang’s best shot for survival was a bone marrow transplant. As an ethnic minority, Huang faced the heightened challenge of locating a “best match” donor from a similar ethnic background. His chances of finding an adult match with a donor of Asian descent, like himself, were estimated at 47%, versus 79% for Caucasian patients. While Huang’s brother was ultimately able to serve as his donor, he still dreamed of a way to ease the bone marrow matching process for other ethnic minorities.

From his hospital bed, Huang drafted what would become “Charlie’s Law”—legislation signed into law by California Gov. Gavin Newsom in 2022, enabling California residents to register for the National Marrow Donor Program when they apply for their driver’s licenses or ID cards.

He partnered with LLS—a leading advocacy organization with allies across California—to help pass the law. “Given the genetic diversity of California...this is going to save lives,” Huang said. Since the registry is national in scope, increasing the number of donors in California can benefit patients throughout the country. But it is Huang’s hope that other states will follow suit to further expand the number of registered donors—and the availability of lifesaving treatment—across the U.S.

...Expanded Latino Outreach

To better serve the large and growing Hispanic population, we established a Latino Outreach Pilot program in the Greater Los Angeles and Central Valley areas of California. Input from local stakeholders, including patients, helped shape the pilot activities, including in-person and online Spanish-language programs. These initial efforts reached over 100,000 individuals affected by blood cancer, along with Promotores (community health workers), and healthcare providers. Evaluative data will guide the program’s future expansion to more cities.

...Improved Access and Diversity in Clinical Trials

LLS believes that the full benefit of cancer research will not be realized until clinical trial participation better reflects the diversity of the U.S. population. We are dedicated to addressing barriers to clinical trial participation to accelerate scientific progress and to provide patients with access to novel therapies and approaches.

Our efforts ramped up in 2022, with the expansion of our LLS IMPACT (Influential Medicine Providing Access to Clinical Trials) Research Grants award. This program is designed to increase the enrollment of individuals from underrepresented communities in clinical trials. This year, we added three more grants expanding this “hub and spoke” model in six geographic locations across the country. The program now provides six “hubs” or major cancer centers with funding to set up networks of trial sites in local community-based hospitals and clinics with significant underserved populations.

Furthermore, we continued to provide financial support to ease the burden of trial participation, particularly for lower income patients and families.
...Sustained Advocacy Efforts

LLS continued to take our messages to influential lawmakers who can advance policies that improve health equity. We are proud to have played a key role in securing:

- **Passage of landmark clinical trial diversity reforms:**
  LLS helped secure the passage of new policies that will enable more patients—including those from groups underrepresented in trials—to access trials. Trial sponsors will now be accountable for diversity targets, and patients should have access to trial services closer to home.

  To move these efforts forward, we held a Virtual Day of Action, during which our advocates sent over 1,400 letters to Congress. LLS Board member Ruben Mesa, M.D. testified before a key congressional committee about the importance of trial diversity. In December, advocates met with nearly 100 Congressional offices to highlight the issue—just weeks before the U.S. House and Senate voted the changes into law.

- **In-network access to cancer centers for Medicaid patients in New York and California.** LLS advocacy was influential in the adoption of a New York law that will designate specialty cancer centers as “in-network” for millions who have health insurance through the marketplace or Medicaid. Our efforts also helped to drive passage of the California Cancer Care Equity Act, which gives the 13 million Californians covered by Medicaid access to specialty cancer centers, even if they’re not in-network. Both laws enhanced coverage through Medicaid which serves patients with lower incomes, and in both states, most patients covered by Medicaid are people of color.

### HEALTH EQUITY BY THE NUMBERS

- **More than $1.3 MILLION** committed by LLS to enhance understanding of disparities in blood cancer care
- **More than 100,000** individuals with blood cancer reached by LLS’ inaugural Latino outreach efforts in California
- **79%** bone marrow matching rate for Caucasian patients; **48%** for Hispanics/Latinos; **47%** for Asians; **29%** for Blacks*
- **SIX MEDICAL CENTERS** using LLS IMPACT grants to expand availability of clinical trials, up from three in 2021
- **Only 5-8%** of blood cancer patients currently enroll in clinical trials; percentages even lower for underserved populations
- **More than 1,400** letters sent to Congress by LLS advocates on our Virtual Day of Action: **381** members of Congress reached

*Source: Be The Match

For more data on how LLS is driving forward health equity, scan here ▶
Patient Financial Assistance

The ever-rising cost of blood cancer care has left patients and families bearing the financial burden. LLS believes no patient should be denied treatment because they cannot afford it. Our financial assistance programs help overcome financial barriers so that patients can access the right care at the right time. This year, we significantly boosted our grants, providing more than $385 million in awards to more than 75,000 patients, up from $241 million to more than 42,000 patients last year.

NEW IN 2022

LLS Scholarship for Blood Cancer Survivors

We are helping young survivors achieve their educational goals, offering scholarships up to $7,500 for one year of higher education tuition. The 100 inaugural recipients spanned 34 states. Nearly one-fifth are first generation college students, and nearly half are studying science, health science, and nursing. Every year, we plan to award new recipients and renew eligible past awardees.

Financial Relief for Patients Impacted by Hurricanes Fiona & Ian

In the wake of the destruction caused by Hurricane Fiona and Hurricane Ian, LLS opened the LLS Financial Relief Fund to help blood cancer patients impacted by the storms in the FEMA designated disaster areas. Blood cancer patients living in declared disaster areas due to Hurricanes Fiona and Ian were eligible to receive a $250 pre-paid VISA card to help offset day-to-day expenses like food, clothing, housing, and gas.

LLS Helps Student’s Dream Come True

The daughter of Ethiopian immigrants, Munira Nuru of Lees Summit, MO, has long possessed a special determination to succeed—a quality she attributes to her family’s unique history. Growing up in Addis Ababa, her parents were taught to value hard work and accomplishment, but were unable to attend college. During her own childhood, Munira’s parents “never failed to instill the value of education,” yet she knew money was tight. To reduce college costs, she took AP and dual-credit classes during high school. But a diagnosis of acute lymphoblastic leukemia (ALL) threw a curveball into her plans. “My concerns switched from trying to spare my parents the overwhelming cost of college to watching them struggle to pay for the medicine I needed to survive,” she said. Although Munira began her bachelor’s degree in biology at a low-cost community college, tuition became challenging when, after two years, she transferred to the University of Missouri, Kansas City. As a recipient of The Leukemia & Lymphoma Society’s Scholarship for Blood Cancer Survivors, she can now continue to pursue the degree she is “passionate about”—happy to show her parents that “all they taught me about hard work, grit, and the value of knowledge has finally paid off.”
One of the worst side-effects of fighting cancer is the cost of care. We are taking bold action to ensure that patients are not the only ones shouldering the rising cost of cancer care.

— Louis J. DeGennaro, PhD, LLS President and CEO

Making Treatments More Affordable for Patient and Families

### 2022 ASSISTANCE FROM OUR SIGNATURE PROGRAMS

<table>
<thead>
<tr>
<th>Program</th>
<th>Funding</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-Pay Assistance Program</td>
<td>$371.5M</td>
<td>36,849</td>
</tr>
<tr>
<td>Helps cover costs for prescription drug insurance, plan premiums and co-pay obligations for specific diseases.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urgent Need Programs</td>
<td>$5.8M</td>
<td>11,763</td>
</tr>
<tr>
<td>Assists patients in acute financial distress with $500 for non-medical costs. In partnership with Moppie’s Love, Charlie’s Fund, and other generous donors.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Aid Program</td>
<td>$1.5M</td>
<td>15,405</td>
</tr>
<tr>
<td>Provides a one-time stipend of $100 for any blood cancer patient with non-medical expenses.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Travel Assistance Programs</td>
<td>$6.5M</td>
<td>11,486</td>
</tr>
<tr>
<td>Helps cover treatment-related transportation and lodging costs. Susan Lang Pay-It-Forward: $500 available every six months. Pre CAR-T-cell Therapy: $2,500 for patients under evaluation for CAR T-cell therapy. New: Multiple Myeloma Fund and the Pediatric Travel Fund.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Patients and their families often experience uncertainty and challenges, from diagnosis through survivorship. LLS is here to answer questions, address concerns, provide support, and foster hope.

— Elisa Weiss, PhD, LLS Senior Vice President, Education, Services, & Health Research

Nearly **1,000 volunteers** dedicated more than **26,000 hours** to help LLS with outreach, information, and support for patients, families, and healthcare providers.

Education and Wellness

LLS is proud to be the leading “go to” source of free information and support for blood cancer patients, families, caregivers, and healthcare professionals. With an extensive array of services and materials, LLS provides essential guidance along the way from diagnosis, treatment to survivorship. This year, we increased outreach and support and expanded our innovative offerings.

**NEW IN 2022**

**Extended Nutrition Service and Resources**

LLS’s proprietary **one-on-one oncology nutrition consultation service** added a second registered dietician, allowing us to **serve over 1,000 patients and caregivers throughout the year**. New resources include printed and online materials for patients and healthcare professionals to raise awareness of patient food insecurity and provide referral resources, and the first in an innovative series of online nutrition-education videos for pediatric cancer families.

**Expanded Survivorship Support**

To better serve those who have completed treatment, we issued numerous podcast episodes. **A Conversation on Adult Survivorship**, for healthcare professionals, had nearly 4,500 listens. Moreover, we released an online and print **LLS Survivorship Workbook**, **used by over 13,000 individuals**. LLS Community, an online social network, created a new **“Ask the Expert” series** which reached almost 20,000 people and won a Bronze Award in the Spring 2022 Digital Health Awards.
Nothing is more important to a parent than their children’s health. In August, 2019, Tim Heberlein of Tampa received word that his two-year old son, Remy, had Pre-B-cell acute lymphocytic leukemia (ALL). A tough three-year treatment journey ensued, including numerous rounds of
Access to Better, More Affordable Care

For decades, LLS has advocated by raising the voices of blood cancer patients and their families. At the heart of our efforts is a nationwide grassroots network of more than 200 volunteer advocacy leaders and 30,000 active online volunteers working hard to effect change. Together, we’ve made a tremendous impact.

New in 2022

Landmark Medicare Law Limits Patients’ Costs
For nearly a decade, LLS has urged lawmakers to limit out-of-pocket drug costs for patients covered by Medicare, since many of those patients spend more than $10,000 a year on treatment. This year, LLS helped pass a transformative law that will cap Medicare beneficiaries’ out-of-pocket prescription drug costs at $2,000 annually. This will transform—and save—lives.

Making Health Insurance Work for Patients
LLS-commissioned research has highlighted the critical role robust provider networks play in assuring patients’ access to timely care. This year, we helped secure a new federal rule requiring insurers to improve provider networks for plans sold through Healthcare.gov and other Affordable Care Act marketplaces. We also aided passage of a new federal policy requiring insurers to offer standardized health plans, including more affordable drug coverage, in the Affordable Care Act marketplaces. And thanks in part to our advocacy, millions of U.S. patients will now enjoy low- or no-cost health insurance premiums for coverage purchased through Healthcare.gov through at least 2025.

Working to Ensure Affordable Drugs for Minnesotans
Thanks to our long-term advocacy, insurance plans will be required to charge an affordable, flat fee for prescription drugs, rather than a percentage of drug costs—a huge savings for those taking expensive specialty drugs. This marks LLS’ third state victory for better insurance coverage of costly drugs in the past three years alone.

Protecting Patients from Surprise Medical Bills
We continued our efforts to influence federal regulations pertaining to implementation of the No Surprises Act (NSA), which ends surprise medical billing. Our involvement included filing legal briefs in numerous court cases dealing with attempts to unravel this Act and making sure states consider patient perspectives as they pass laws and rules related to these protections.

Leading Efforts to Put an End to Junk Insurance
As a nationwide leader in the battle against “junk” insurance policies (that discriminate against those with cancer and other serious health conditions), we made headway in Kansas, helping to defeat a measure that would have expanded availability of these plans. Additional progress was made in Colorado, where we helped secure a law that will enable regulators to gather more information about these dangerous policies. We continue to advocate for stronger federal protections.

chemotherapy, but thankfully, in October 2022, Remy got to “ring the bell” signaling the end of his treatments. While his son’s treatments have ceased, Tim’s desire to fight for the rights of fellow blood cancer patients remains in full swing. In 2021, in the midst of Remy’s cancer battle, he was appointed the LLS Advocacy Leader in Florida. In this role, he leads a robust committee of advocacy volunteers responsible for helping advance the LLS Office of Public Policy’s (OPP) goals. Tim provides strategic direction, including identification of new advocacy volunteers, and helps develop advocates’ skills so they, too, can effectively influence lawmakers to take action on issues critical to the blood cancer community. His invaluable 2022 contributions to LLS included building relationships with his members of Congress and their staff and urging them to take action on specific pediatric policy priorities. Tim accomplished this through visits in the district and virtually in Washington D.C. as part of LLS’s Lobby Day and the Alliance for Childhood Cancer Action Day.
Passionate Philanthropy
Making An Impact

A “Village” Of Dreamers Helps Advance Our Mission

If it sometimes takes a village to achieve one’s goals, LLS is fortunate to have such a community: the thousands of volunteers, donors, and corporate partners that, each year, help us raise the funds we need to conquer blood cancer.

In 2022, receding COVID-19 restrictions allowed us to begin transitioning back to in-person fundraising events, with great success. Participants across the globe crossed long-awaited finish lines, hit the slopes, hiked to new heights, and participated in virtual challenges...setting records in the process. The following LLS “village superstars” represent but a sampling of our dedicated supporters.

Adam Neary: National Man of the Year (MOTY)
A Principal at WealthOne, LLC, Adam of Albany, NY, competed for LLS National MOTY, aiming for the highest total raised over a 10-week campaign. His mission was accomplished, bringing in $1,095,692 to support LLS. Adam’s participation was in honor of his friend and mentor, Todd Slingerland, who was diagnosed with an aggressive lymphoma in spring 2021. While Todd fortunately reached remission after several months of treatment, Adam’s drive was unabated. “Todd is a survivor today because of the investment, research, and support for which LLS tirelessly champions,” he said. “Just because Todd’s cancer is dormant, doesn’t mean we can be—the fight continues, until we find a cure.”

Emily Lipman Mahar: National Woman of the Year (WOTY)
After losing her mother, Eva Goldberg Lipman, to Hepatosplenic Gamma Delta T-cell lymphoma, a rare form of lymphoma in November 2020, Emily, owner of Emily Lipman Designs in Atlanta, turned her pain into passion by running for National WOTY. “I accepted this nomination knowing it would be difficult, but also I knew this was the way to honor my mother,” she said. “[My mother] gave back in so many ways, and now it was my turn. No family should have to experience the devastation of cancer.” Lipman Mahar’s record-setting $1,001,911 raised made her the first National WOTY to raise over $1 million in the campaign’s over 30-year history.
Jordan Loughran, Alice Voigt, and Barrett Hight: Students of the Year (SOY)

Three Atlanta high school juniors, all touched by blood cancer, formed “The Answer for Cancer” fundraising team. Leveraging their own musical talents to create an inspiring song video with over 1,000 YouTube views, they raised $559,366 for LLS—a record for the LLS Georgia-South Carolina Region. “As I got older, I became aware of the massive impact LLS’s funding played in my cancer journey,” said Loughran, a 13-year leukemia survivor. Hight (18) participated to honor Loughran, and his grandmother, a non-Hodgkin lymphoma patient. And Voight (17) lent her singing voice in tribute to her cousin, Garland, diagnosed with Hodgkin lymphoma. “Why should our age limit us in galvanizing together with our communities so that one day, nobody has to hear the word ‘cancer?’” Voight said.

John Reumann: Team In Training

Before learning of his own Chronic Lymphocytic Leukemia (CLL) diagnosis in 2013, John, an avid cyclist, marketing vice president, and current Chairman of the Board of Trustees for the Rocky Mountain Region, had participated in events that raised money for “virtually every charitable cause.” Once diagnosed, he joined LLS Team in Training (TNT) and formed Team Survivor, raising over $750,000 to LLS research. In his 2022 ride, his 9th, the Denver area resident journeyed with his team to Lake Tahoe and raised $125,000 to provide funding for a research portfolio—earning an LLS Impact Award in the process. “I will continue to ride for my friends who are in treatment and for those we have lost to this disease,” he stated, pledging he will “try to ride faster than Leukemia.”

Dr. Marvin Connelly: Light The Night (LTN)

After learning he had cancer in February 2019, Marvin was “ready to battle and fight hard.” This Fayetteville, NC school superintendent and pastor took inspiration from Layla Smith, a second grade blood cancer survivor at one of his schools. “Her story encouraged me along my journey and is part of the ‘WHY’ I wanted to be involved with LLS,” he said. Fighting for “many more Laylas,” Marvin helped his district raise over $100,000 for LLS in the last two years, including $70K in FY22—with plans to raise an additional $60K for his 60th Birthday. Along with a group of district staff and students, Marvin attended his first in-person LTN event in Raleigh in October, honoring Layla. He called it “an amazing event... one of the highlights of my lifetime.”

Gentile Family: Big Climb

In the summer of 2021, David and Heather Gentile of Haddon Twp, NJ, grew concerned over their two-year-old daughter Grace’s health. Multiple infections and uncharacteristically low energy led to various pediatrician appointments, a visit to the local ER, and a transfer to Philadelphia Children’s Hospital where doctors diagnosed B Cell Acute Lymphocytic Leukemia (ALL). Months of grueling treatments followed, including intensive chemotherapy, but by May 2022, Grace was placed on a maintenance treatment. That same month, the Gentile family participated in Big Climb Philadelphia, as part of the corporate team formed by David’s employer, Admiral Insurance—raising $13,740 for LLS’ mission. Despite “bumps in the road,” David relayed that Grace, now in preschool, “continues to thrive, plays tots soccer, and has hopes of being a mermaid doctor when she grows up.”
Jim Beck, Pennsylvania

"My brother Bobby died of leukemia on Christmas Day in 1951 at the age of 4, before I was born. For more than 40 years, my family and I have contributed to LLS, and by far the most meaningful impact we have made is through our support of LLS’s new book trilogy for pediatric patients and their families, entitled The Stars Will Twinkle, The Sun Will Shine. My older brother Johnny was 7 when Bobby died; when Johnny read the trilogy, he said that having this resource would have made a world of difference for him and our family."

Amy Lee, Texas

"As a current survivor of stage IV aggressive diffuse large b-cell non-Hodgkin lymphoma, I know firsthand how important it is to support LLS’s efforts. In fact, one of my curative measures was funded by LLS. Our family is honored to support Student Visionaries of the Year, Light the Night, and the Dare to Dream Project. I am not in control of the cancer coming back, but I AM in control of being positive, having faith over fear and making it my lifelong mission to give back and to support those who receive a cancer diagnosis."

Please visit www.LLS.org/AnnualReport to read our full Fiscal Year 2022 Annual Report, including acknowledgments.
Thank You

As always, LLS gratefully thanks all of our dedicated volunteers and donors who help make our lifesaving work possible. Whether raising critical funds, advocating for lifesaving policies, providing support to those impacted by cancer, or building critical capacity, our donors, volunteers and supporters are invaluable as we continue to advance the LLS mission.

Pablo Legorreta,
Chief Executive Officer,
Royalty Pharma, New York

“Despite many advances in blood cancer care and treatment, barriers exist in many communities to prevent patients from accessing new, more effective therapies and protocols that can lead to better outcomes. The gift awarded through Royalty Pharma’s alliance with The Leukemia & Lymphoma Society is intended to propel the work LLS is doing in underserved communities through three key initiatives that will help break down these barriers and ensure that everyone has access to the care they need to treat their blood cancer.”

Greg and Marcie Sinaiko, California

“My wife Marcie and I first got involved with LLS following my diagnosis with Hodgkins lymphoma in 2017. I needed a stem cell transplant and was referred to the Information Resource Center for information on how to proceed with the treatment. Following my treatment and ultimate recovery, my entire family became very involved with LLS. I joined the Greater Los Angeles Board in 2019, where I currently serve as Board Chair. Our middle daughter, Samantha, was a Student of the Year candidate in 2021, our youngest daughter is on a team in 2022, and Marcie has been on the Visionary of the Year committee. Our family has gathered a large group of team participants for the past two Light the Nights and we have generously supported innovative research led by LLS in the pursuit of an ultimate cure for Hodgkins lymphoma.”

The Harry T. Mangurian, Jr. Foundation, Florida

“Since its inception in 1999, The Harry T. Mangurian, Jr. Foundation has built an ongoing partnership with The Leukemia & Lymphoma Society. While leukemia claimed the life of our founder, his legacy has lived on through the Foundation’s participation in the Beat AML Master Clinical Trial and the Children’s Initiative. Further, throughout our relationship, the transparency and stewardship provided by LLS to all of its supporters through interim and annual reporting has shown that exceptional progress has been realized through research, clinical trials and, most importantly, the saving of lives. We are proud to be a part of the team leading the fight to eradicate this disease.”

AbbVie Inc.
Amgen Inc.
BeiGene, Ltd.
Bristol Myers Squibb
Burlington

Eli Lilly and Company
Gateway for Cancer Research
Genentech Inc.
Gilead Sciences, Inc.

GSK (formerly known as GlaxoSmithKline)
Janssen Biotech
Jazz Pharmaceuticals
Kite, A Gilead Company

Pfizer Inc.
Pharmacyclics, An AbbVie Company & Janssen Biotech
Royalty Pharma

Subaru of America Inc.
Takeda Oncology
Walgreens
Wawa
2022 was a year of important transformation and significant milestones for LLS. We celebrate our achievements, but our work goes on and **our dreams continue**. We will continue to pursue **bold progress** across all our mission priorities, until we realize our mission’s end goal: a **world without blood cancers**.

Our priorities include…

**Outsmarting Cancer Through Research**
One of the world’s leading funders and authorities on blood cancer research, LLS has contributed to nearly every new treatment in recent decades.

**Advancing Health Equity**
LLS is committed to making sure ALL blood cancer patients have access to and receive the treatment they need, regardless of location, race, language, or income.

**Supporting Survivors**
LLS recognizes blood cancer patients have a lifelong journey to navigate and we are here for them, from diagnosis and treatment, through remission and beyond.

**Patient Financial Assistance**
LLS is committed to relieving the financial burdens felt by patients who are coping with blood cancer through our Patient Financial Assistance Programs.
Improving Access to Clinical Trials
LLS is dedicated to helping patients access clinical trials to improve the care and treatment they receive for their specific blood cancer.

Access, Quality and Affordability of Care
To give them their best chance for a cure and long-term quality of life, LLS is continually advocating to ensure all patients receive the best healthcare available.

Education & Wellness
Every step of the way, LLS is the leader in free information and comprehensive support for blood cancer patients, families, and healthcare professionals.

Dare To Dream Project
With The Dare to Dream Project, LLS is ushering in a new era of pediatric research, treatment, and care for children with cancer.
Your Support is Invested Wisely

In fiscal year 2022, LLS raised $444 million to support our mission and operations. We spent $434 million—or 81% of our expenses—on specific programs designed to find new treatments for blood cancers, provide financial assistance to blood cancer patients, break down barriers to care, and improve the lives of patients and their families.

Operations Makes the Mission Possible! Operational costs fuel the various ways LLS supports patients and families: from the free personalized assistance offered in our Information Resource Center and Clinical Trial Support Center; to podcasts, chats and opportunities to connect with others in our online community; to Virtual Blood Cancer Conferences staffed with experts in the field.

CONSOLIDATED STATEMENT OF ACTIVITIES
For the year ended June 30, 2022 (USD Thousands)

<table>
<thead>
<tr>
<th>Revenue</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>$ 284,823</td>
</tr>
<tr>
<td>Less: direct donor benefit costs</td>
<td>(15,474)</td>
</tr>
<tr>
<td><strong>Net campaign contributions</strong></td>
<td>$ 269,349</td>
</tr>
<tr>
<td>Co-Pay contributions</td>
<td>$ 129,256</td>
</tr>
<tr>
<td>Royalties and other income</td>
<td>$ 37,055</td>
</tr>
<tr>
<td>Net interest and dividend income</td>
<td>$ 8,204</td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td>$ 443,864</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Operating Expenses</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>$ 94,190</td>
</tr>
<tr>
<td>Patient and Community Service</td>
<td>$ 304,208</td>
</tr>
<tr>
<td>Public Health Education</td>
<td>$ 22,899</td>
</tr>
<tr>
<td>Professional Education</td>
<td>$ 12,444</td>
</tr>
<tr>
<td><strong>Total Program Services</strong></td>
<td>$ 433,741</td>
</tr>
</tbody>
</table>

| Supporting Services                   |                |
| Management and general                | $ 54,039       |
| Fundraising                           | $ 46,457       |
| **Total Supporting Services**         | $ 100,496      |

| **Total operating expenses**          | $ 534,237      |
| Foreign currency loss                 | (478)          |
| Net Increase in fair value of investments | (51,949) |
| **Change in net assets**              | (142,800)      |

CONSOLIDATED BALANCE SHEET
As of June 30, 2022 (USD Thousands)

<table>
<thead>
<tr>
<th>Assets</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 10,996</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>$ 5,861</td>
</tr>
<tr>
<td>Contributions and other receivables, net</td>
<td>$ 25,382</td>
</tr>
<tr>
<td>Investments</td>
<td>$ 402,862</td>
</tr>
<tr>
<td>Investments held for Co-Pay program</td>
<td>$ 250,026</td>
</tr>
<tr>
<td>Fixed assets, net</td>
<td>$ 10,915</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$ 706,042</td>
</tr>
</tbody>
</table>

| Liabilities                           |                |
| Accounts payable and accrued expenses | $ 25,729       |
| Deferred revenue                      | $ 14,134       |
| Awards and grants payable             | $ 50,225       |
| Co-Pay assistance payable             | $ 229,195      |
| Other long-term liabilities           | $ 4,570        |
| **Total liabilities**                 | $ 323,853      |

| Net assets                            |                |
| Without donor restriction              | $ 316,414      |
| With donor restriction                 | $ 185,183      |
| **Total net assets**                   | $ 382,189      |
| **Total liabilities and net assets**   | $ 706,042      |
AT LLS, WE BELIEVE...

GIVING IS PERSONAL.
Contributions don’t come from the wallet—they come from the heart. We respect how deeply our donors feel about what we do and why we do it.

GIVING IS COMMUNITY.
A shared passion for change unites us. No matter where we live or who we are, we are together as one for a common cause.

GIVING IS GOOD.
Our donors believe in sharing their resources willingly for the good of all, not just themselves.

GIVING IS HONEST.
We are always open about how, why, where, and when we use your contributions.

GIVING IS IMPACT.
We strive to make a meaningful difference in the lives of those around us and for those we may never meet.

THANK YOU FOR GIVING.
Your generosity makes our work possible, and we promise to uphold your trust in us.
LLS is proud to be recognized as a *Fast Company* 2022 Brand That Matters. LLS is the only cancer organization on the list and the only healthcare organization in the not-for-profit category.

LLS has a Four-Star Rating from Charity Navigator, *America's largest independent charity evaluator*. This rating designates LLS as an official “Give with Confidence” charity, indicating that our organization is using its donations effectively.

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. Find out more at [www.LLS.org](http://www.LLS.org).